Allergan is paying a stunning 500% premium to buy a clinical-stage biotech By: MarketWatch September 20, 2016 at 14:27 PM EDT The usual premium on a company with no approved drugs is closer to 50% to 100%, says RBC. Read More >> Related Stocks: Allergan Plc Astrazeneca Plc ADR Bristol-Myers Squibb Galmed Pharmaceutica Gilead Sciences Intercept Pharmaceuticals Novartis Ag ADR
